- Conditions
- Neutropenia, Sickle Cell Disease
- Interventions
- Decitabine
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 10,540
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Choroideremia
- Interventions
- 4D-110
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Salt Lake City, Utah
- Conditions
- Hypospadias, Penile Torsion, Chordee, Phimosis
- Interventions
- Caudal Block, Ultrasound-guided Pudendal Block, Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine, Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine.
- Procedure · Drug
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 6 Months to 3 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Lysosomal Storage Diseases
- Interventions
- Not listed
- Lead sponsor
- Lysosomal and Rare Disorders Research and Treatment Center, Inc.
- Other
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- entinostat
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Hailey Hailey Disease
- Interventions
- Guselkumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Facial Neoplasms, Head and Neck Neoplasms, Head Injuries, Penetrating, Birth Injuries
- Interventions
- Chlorinated polyethylene elastomer
- Combination Product
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Male Factor Infertility, Female Factor Infertility
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia
- Interventions
- cediranib maleate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Jacksonville, Florida • Baltimore, Maryland + 2 more
- Conditions
- Cystic Fibrosis
- Interventions
- Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase)
- Other
- Lead sponsor
- Nicole Hamblett
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more
- Conditions
- Atopic Dermatitis
- Interventions
- Rocatinlimab vial injection, Rocatinlimab prefilled syringe
- Drug · Combination Product
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
- Conditions
- Kartagener Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Not listed
- Enrollment
- 1,800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Sickle Cell Disease
- Interventions
- WE CARE SDoH Screening Survey, Family Resource Book, Standard of care
- Behavioral · Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Fragile X Syndrome, Healthy Volunteers
- Interventions
- [15-O]water
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 24 Years · Male only
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Atopic Dermatitis
- Interventions
- Placebo, Upadacitinib, Topical corticosteroids (TCS)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 1,533 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
- Conditions
- Down Syndrome
- Interventions
- 2 months of drumming lessons given by a professional drummer with extensive experience working with children with Down syndrome, Lessons after measurement
- Behavioral
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 7 Years to 15 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
- Interventions
- Guanfacine Extended Release, Placebo
- Drug · Other
- Lead sponsor
- Maimonides Medical Center
- Other
- Eligibility
- 6 Years to 35 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Breast Cancer, Prostate Cancer
- Interventions
- Soy Isoflavone Nutritional Supplements
- Drug
- Lead sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- NIH
- Eligibility
- Not listed
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Hypospadias, Surgery Non Hypospadias
- Interventions
- Measurement in Office, Measurement in OR
- Procedure
- Lead sponsor
- Albany Medical College
- Other
- Eligibility
- Male only
- Enrollment
- 410 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Albany, New York
- Conditions
- Macular Degeneration
- Interventions
- intravitreal injection Lucentis (ranibizumab)
- Drug
- Lead sponsor
- Retina Research Foundation
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Slingerlands, New York
- Conditions
- Sleep Apnea, Obstructive, Respiration Disorders
- Interventions
- supraglottoplasty with laser
- Procedure
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2019
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Tildacerfont/Placebo
- Drug
- Lead sponsor
- Spruce Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more
- Conditions
- Fragile X Syndrome, Autism Spectrum Disorders
- Interventions
- Acamprosate
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Desmoplastic/Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma With Extensive Nodularity, Nevoid Basal Cell Carcinoma Syndrome
- Interventions
- Carboplatin, Cognitive Assessment, Cyclophosphamide, Etoposide, Laboratory Biomarker Analysis, Methotrexate, Vincristine Sulfate
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 47 Months
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 158
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 126 more